Skip to main content
Top
Published in: Journal of Nuclear Cardiology 3/2010

01-06-2010 | Review Article

The emerging role of the selective A2A agonist in pharmacologic stress testing

Authors: Anthony S. Gemignani, MD, Brian G. Abbott, MD

Published in: Journal of Nuclear Cardiology | Issue 3/2010

Login to get access

Excerpt

Since its inception almost 50 years ago, the technique of myocardial perfusion imaging has evolved substantially. From pyrophosphate to Tl-201 to technetium-based radiotracers, from static planar imaging to gated SPECT with attenuation correction, the field of nuclear cardiology has matured with these significant technical advances. Similarly, the use of pharmacologic stressors as an alternative to exercise has also been in a state of evolution, from dipyridamole and dobutamine to adenosine, to a novel agent recently approved and available for use. This review will highlight recent developments in pharmacologic stress myocardial perfusion imaging focusing on the clinical application of the selective adenosine A2A receptor agonists. …
Literature
1.
go back to reference Miyamoto MI, Vernotico SL, Majmundar M, Thomas GS. Pharmacologic stress myocardial perfusion imaging: A practice approach. J Nuc Cardiol 2007;14:250-5CrossRef Miyamoto MI, Vernotico SL, Majmundar M, Thomas GS. Pharmacologic stress myocardial perfusion imaging: A practice approach. J Nuc Cardiol 2007;14:250-5CrossRef
2.
go back to reference Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results of the Adenoscan Multicenter Trial Registry. JACC 1994;23(2):384-9PubMed Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results of the Adenoscan Multicenter Trial Registry. JACC 1994;23(2):384-9PubMed
3.
go back to reference Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nuc Cardiol 2007;14:645-58CrossRef Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nuc Cardiol 2007;14:645-58CrossRef
4.
go back to reference Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist, regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. JACC Imaging 2008;1:307-16CrossRef Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist, regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. JACC Imaging 2008;1:307-16CrossRef
5.
go back to reference Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the advance MPI 2 trial. JACC Imaging 2009;2:959-68CrossRef Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the advance MPI 2 trial. JACC Imaging 2009;2:959-68CrossRef
7.
go back to reference Mekkaoui C, Jadbabaie F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, et al. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-SestaMIBI biodistribution and kinetics. JACC Imaging 2009;2:1198-208CrossRef Mekkaoui C, Jadbabaie F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, et al. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-SestaMIBI biodistribution and kinetics. JACC Imaging 2009;2:1198-208CrossRef
8.
go back to reference Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nuc Cardiol 2007;14:514-20CrossRef Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nuc Cardiol 2007;14:514-20CrossRef
9.
go back to reference Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007;49(6):369-75CrossRefPubMed Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007;49(6):369-75CrossRefPubMed
10.
go back to reference Gaemperli O, Schepis T, Koepfli P, Siegrist PT, Fleischman S, Nguyen P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008;51:328-9CrossRefPubMed Gaemperli O, Schepis T, Koepfli P, Siegrist PT, Fleischman S, Nguyen P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008;51:328-9CrossRefPubMed
11.
go back to reference Samady H, Wackers FJ, Joska TM, Zaret BL, Jain D. Pharmacologic stress perfusion imaging with adenosine: Role of simultaneous low-level treadmill exercise. J Nuc Card 2002;9(2):188-96CrossRef Samady H, Wackers FJ, Joska TM, Zaret BL, Jain D. Pharmacologic stress perfusion imaging with adenosine: Role of simultaneous low-level treadmill exercise. J Nuc Card 2002;9(2):188-96CrossRef
12.
go back to reference Holly TA, Satran A, Bromet DS, Mieres JH, Frey MJ, Elliott MD, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial. J Nuc Card 2003;10(3):291-6CrossRef Holly TA, Satran A, Bromet DS, Mieres JH, Frey MJ, Elliott MD, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial. J Nuc Card 2003;10(3):291-6CrossRef
13.
go back to reference Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active- controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nuc Card 2009;16(1):63-72CrossRef Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active- controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nuc Card 2009;16(1):63-72CrossRef
14.
go back to reference Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, and adenosine A2A agonist for myocardial perfusion imaging, in mild asthma patients: A randomized, double-blind, placebo-controlled trial. J Nuc Card 2008;15(3):329-36CrossRef Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, and adenosine A2A agonist for myocardial perfusion imaging, in mild asthma patients: A randomized, double-blind, placebo-controlled trial. J Nuc Card 2008;15(3):329-36CrossRef
15.
go back to reference Thomas GS, Tammelin BR, Schiffman GL. Safety of regadenoson, a selective A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial. J Nuc Card 2008;15(3):319-28CrossRef Thomas GS, Tammelin BR, Schiffman GL. Safety of regadenoson, a selective A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial. J Nuc Card 2008;15(3):319-28CrossRef
16.
go back to reference Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33CrossRefPubMed Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33CrossRefPubMed
17.
go back to reference Laighold S, Druz R. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nuc Card 2009;16:478-80CrossRef Laighold S, Druz R. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nuc Card 2009;16:478-80CrossRef
18.
go back to reference Al Jaroudi W, Hermann D, Hage F. Safety of Regadenoson in patients with End-Stage Renal Disease. Am J Cardiol 2010;105:133-5CrossRef Al Jaroudi W, Hermann D, Hage F. Safety of Regadenoson in patients with End-Stage Renal Disease. Am J Cardiol 2010;105:133-5CrossRef
Metadata
Title
The emerging role of the selective A2A agonist in pharmacologic stress testing
Authors
Anthony S. Gemignani, MD
Brian G. Abbott, MD
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Journal of Nuclear Cardiology / Issue 3/2010
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-010-9211-9

Other articles of this Issue 3/2010

Journal of Nuclear Cardiology 3/2010 Go to the issue